Mustang Bio is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.
Location: United States, Massachusetts, Worcester
Investors 3
Mentions in press and media 12
| Date | Title | Description |
| 02.05.2024 | Mustang Bio Announces Closing of $4 Million Public Offering | - |
| 30.04.2024 | Mustang Bio Announces Pricing of $4 Million Public Offering | WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies i... |
| 29.04.2024 | Mustang Bio Announces Pricing of $4 Million Public Offering | - |
| 11.03.2024 | Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights | - |
| 11.03.2024 | Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights | WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies i... |
| 07.03.2024 | Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma | - |
| 03.08.2023 | Mustang Bio to Participate in Two August 2023 Investor Conferences | WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cure... |
| 08.03.2022 | Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital | WORCESTER, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cur... |
| 01.11.2021 | Mustang Bio, Inc. Receives a Grant of Approximately $2 Million from the National Cancer Institute of the National Institutes of Health | Mustang Bio, Inc. announced that the company has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (?NIH?). This two-year award will partially fund the Phase 1, Open Lab... |
| 09.09.2018 | In-house CAR-T manufacturing preferable to outsourcing, execs say | With their Food and Drug Administration approval last year and European Medicines Association approval this year, the two marketed CAR-T products – Novartis’ Kymriah (tisagenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel)... |
Show more